A 20 billion R&D giant pharmaceutical company will appear!

Medical Network News on July 9 A few days ago, BeiGene Science and Technology Innovation Board (initial launch) applied for a meeting, which aroused high attention from the market, which means that the company is one step closer to becoming the first pharmaceutical company to be listed in the three places
.
According to statistics, in the first half of this year, 29 pharmaceutical companies landed on A-shares.
Among them, 8 companies including Olin Biotechnology and Kain Technology have gross profit margins exceeding 80%
.
Zhonghong Medical’s net profit has soared 28 times a year, from 90 million yuan to 2.
6 billion yuan; 100 billion market capitalization pharmaceutical company "A split A" successfully listed, Changchun Hi-tech Holdings subsidiary Baike Biologics listed on the Sci-tech Innovation Board; Baiyang Pharmaceutical Two Shandong companies from Weigao Orthopedics went public on the same day
.
Entering the second half of the year, Shuyu Civilian took the lead in listing, and Warner Pharmaceuticals entered the stage of IPO subscription
.
In addition, over 70 pharmaceutical companies are on the way to IPO, 18 companies including Chengdu Better Pharmaceuticals, Sichuan Huiyu Pharmaceuticals, and Shanghai Yizhong Pharmaceuticals have submitted registrations; 7 companies including BeiGene and Guangdong Wannianqing Pharmaceuticals have met; Enwei Pharmaceuticals 38 companies including Shanghai Xuantai Pharmaceutical have inquired, and 11 companies including Tianjin Tongrentang Group and Rongchang Biopharmaceutical have accepted
.
According to data, in 2019, there were 18 pharmaceutical companies listed, and in 2020, there will be 42 companies
.
According to industry analysts, with the epidemic under control and consumption recovery, A-share IPOs have basically returned to normal in the first half of this year, and the number has increased significantly over the same period last year
.
It is expected to maintain a strong momentum throughout the year .

　　29 listed in the first half of the year !
A pharmaceutical company with a market value of 100 billion yuan "A split A ", this pharmaceutical company whose net profit ranges from 90 million to 2.
6 billion A-share listed pharmaceutical companies in the first half of 2021 Note: Total market value, increase and decrease as of June 30, 2021 * is the gross profit margin More than 80% of companies
　　Zhonghong Medical: a 28- fold increase in a year , and net profit from 90 million to 2.
6 billion
In April this year, Zhonghong Medical officially landed in A shares.
The company is mainly engaged in the R&D, production and sales of high-quality nitrile gloves, PVC gloves and other medical and industrial disposable protective gloves
.
According to data, the company's revenue in 2020 was 4.
778 billion yuan, a year-on-year increase of 308%; net profit was 2.
664 billion yuan, a year-on-year increase of 2884%, and the net profit in 2019 was only 89.
27 million yuan
.
The company's performance continued to soar in the first quarter of this year, with revenue of 2.
273 billion yuan, an increase of 588% year-on-year; net profit of 1.
402 billion yuan, an increase of 2437% year-on-year
.
Regarding the soaring performance, Zhonghong Medical said that due to the impact of the new crown pneumonia epidemic, the demand for disposable protective gloves and the sales price have continued to rise since 2020, coupled with the release of the company's Jiangxi Zhonghong production capacity and the increase in product production and sales, the company's performance has increased significantly
.
The global epidemic continued to spread in the first quarter of this year, the tight supply and demand situation of disposable health protective gloves has not been significantly eased, and product sales prices have continued to be high compared with the same period last year
.

　　Baike Bio: 100 billion market capitalization pharmaceutical company "A Split A " successfully landed
on the Sci-tech Innovation Board On June 25, the 100 billion market capitalization Baik Biotech's holding subsidiary of Changchun Hi-tech successfully landed on the Sci-tech Innovation Board, and it soared by more than 200% on the same day.
At present, the market value exceeds 40 billion yuan
.
Statistics show that one hundred grams organisms is a major commitment to prevention and treatment of infectious diseases innovative bio- pharmaceutical enterprises, there are chicken pox vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine has been approved for three kinds of vaccine products, also has a 14 in Research vaccines and 2 fully human monoclonal antibodies under development for the prevention and control of infectious diseases
.
Baike Biotech stated that this spin-off will make the main business structure of Changchun Hi-tech and Baike Biotech clearer.
Baike Bio will rely on the science and technology innovation board platform/independent/independent financing to promote the development of its own main business, which is conducive to the promotion of listing The overall profitability of the company and Beike Biotechnology in the future will enhance its comprehensive competitiveness
.
In the first quarter of this year, Baike's revenue was 247 million yuan, a year-on-year increase of 24.
12%; net profit was 55.
42 million yuan, a year-on-year increase of 11.
13%; gross profit margin reached 88.
30%
.
Recently, Changchun Hi-tech announced that its subsidiary Jinsai Pharmaceutical plans to acquire a 51% stake in Beijing Xinyuan Evergreen
.
It is understood that Beijing Xinyuan Evergreen is a high-tech biotechnology company focusing on protein biomarker testing for neurodegenerative diseases, mainly focusing on two kinds of Alzheimer's disease marker detection and auxiliary diagnosis kits
.
Changchun Hi-tech stated that from the perspective of the company’s sustainable development, this foreign investment is conducive to broadening the company’s business structure, prompting the company to quickly enter the field of elderly neurodegenerative diseases, helping to improve the product line layout in strategic areas, enhance technical reserves, and upgrade the core Competitiveness
.

　　Two Shandong companies, Baiyang Pharmaceutical and Weigao Orthopedics, were listed
on the same day.
On June 30, Shandong-based Baiyang Pharmaceutical and Weigao Orthopedics landed on A shares on the same day.
Both share prices rose sharply at the close of the day.
Among them, Baiyang Pharmaceuticals soared by 635.
08%.
, The market value of 29.
5 billion yuan; Weigao Orthopedics soared 192.
79%, the market value of 42.
4 billion yuan
.
Baiyang Pharmaceutical: The company is a professional pharmaceutical product commercialization platform.
Its main business is to provide comprehensive marketing services for pharmaceutical product manufacturers, including providing brand operation, wholesale distribution and retail of pharmaceutical products, and is committed to becoming a connection between pharmaceutical products and downstream consumption The bond of the author provides comprehensive solutions for product marketing for brand-name pharmaceutical manufacturers
.
Regarding the future development, Baiyang Pharmaceutical stated that in accordance with the company’s overall development strategy, combined with the investment project construction of this issuance, the company will continue to adhere to the increasing health needs of consumers as the guide, expand the brand matrix, upgrade the marketing system, and increase Greater informatization strength, increasing the scale of logistics distribution and retail chain, strengthening e-commerce capabilities, and constantly strengthening the company’s competitive advantages, forming a benign development environment of "brand-platform-ecological circle"
.
Weigao Orthopedics: The company’s main business is the R&D, production and sales of orthopedic medical devices .
The main products include orthopedic implanted medical devices and orthopedic surgical devices.

.
In the field of orthopedic implantable medical devices, the company is the product range, leading scale, with the market competitiveness of enterprises one
.
According to data, in July 2020, Weigao Orthopedics started the spin-off and listing process of Weigao Orthopedics; on June 1 this year, Weigao Orthopedics was approved by the China Securities Regulatory Commission and the registration took effect
.
In the first quarter of this year, Weigao Orthopedics revenue was 421 million yuan, a year-on-year increase of 46.
71%; net profit was 11,100 yuan, a year-on-year increase of 101.
51%, and the gross profit margin exceeded 80%
.

In the second half of the year: Shuyu civilians took the lead in listing, 18 Beite and Huiyu first declared, and 20 billion R&D giants came to the
medical enterprise registration system review statistics As of July 3, entering the second half of the year, Shuyu civilians took the lead in listing , Warner Pharmaceuticals entered the new share subscription stage .
In addition, over 70 pharmaceutical companies are on the way for IPOs.
18 companies including Chengdu Better Pharmaceuticals, Sichuan Huiyu Pharmaceuticals, Shanghai Yizhong Pharmaceuticals, Liaoning Chengda Biologics, and Beijing Yiqiao Shenzhou have submitted registrations; BeiGene and Guangdong Wannianqing Seven pharmaceutical companies, including BeiGene, are expected to become the first pharmaceutical company listed on the "A%20H%20N" three places.
From 2017 to the first three quarters of 2020, the company has invested nearly 20 billion yuan in R&D; Enwei Pharmaceutical 38 companies, including Anhui Chinese Health Medicine, First Pharmaceutical Holdings, and Shanghai Xuantai Pharmaceutical, have inquired, and 11 companies including Tianjin Tongrentang Group and Rongchang Biopharmaceutical have accepted .
According to the prospectus (draft), BeiGene has invested nearly 20 billion yuan in R&D from 2017 to the first three quarters of 2020, accounting for 270.
05% of revenue .
At present, the company has a total of 3 self-developed drugs in the commercialization stage: BTK small molecule inhibitor Baiyueze (Zebutinib Capsules), anti-PD-1 monoclonal antibody Bezean (Tilelizumab injection) ) And PARP inhibitor Baihuize (Pamipali Capsules) .
The company has 47 commercial products and clinical stage drug candidates, including 8 commercial stage drugs 6, 4 declared drug candidates and 35 7 clinical stage drug candidates　　




.
Among them, the company has 3 self-developed drugs on the market, 8 self-developed drug candidates are in the clinical research stage, and 36 cooperative products are in the clinical or commercialization stage
.
In June of this year, Baizean has been approved for two new indications.
At present, the product has been approved for 5 indications
.
It is worth mentioning that the company intends to raise 20 billion yuan for drug clinical trial research and development projects, R&D center construction projects, production base research and development and industrialization projects, marketing network construction projects and supplementary working capital, with a total investment of 22.
3 billion yuan.

.


A few days ago, Livzon Group issued an announcement stating that its shareholding company Tianjin Tongrentang Group (referred to as Jintongrentang) recently submitted an application for an initial public offering and listing on the ChiNext to the Shenzhen Stock Exchange, and obtained the Shenzhen Stock Exchange on June 28, 2021.
The "Notice on Accepting the Application Documents for Tianjin Tongrentang Group Co.
, Ltd.
's Initial Public Offering and Listing on the ChiNext", the Shenzhen Stock Exchange accepted the application documents for Tianjin Tongrentang's IPO and listing on the ChiNext
.
Jintong Rentang will cooperate with the review of the issuance and listing in accordance with the relevant requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange
.
The company holds 44 million shares of Jintong Rentang, accounting for 40% of the total share capital of Jintong Rentang before its initial public offering
.
According to the prospectus (application draft) of Jintongrentang, the company is mainly engaged in the research and development, production and sales of Chinese patent medicines.
The products cover 8 dosage forms including tablets, hard capsules, granules, syrups, and oral liquids, and the treatment fields include urinary medicine.
Kidney disease, cardio-cerebrovascular disease and peripheral vascular disease in the system
.
At present, the company has 114 drug approval numbers, 32 drugs are included in the National Medical Insurance Catalog, and 11 drugs are included in the National Essential Drug List
.
The company's operating income mainly comes from three varieties of Nephritis Kangfu tablets, Xuefu Zhuyu capsules and Vaifukang tablets
.

　　Source: Oriental Fortune.
com, Announcements of Listed Companies Note: If there are any omissions, please correct me!